{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu X"],"funding":["National Key R&amp;D Program of China","Zhejiang Research Center of Cardiovascular Diagnosis and Treatment Technology","Zhejiang Province Science and Technology Department Key R&amp;D Program","The National Natural Science Foundation of China"],"pagination":["6502"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9655232"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(21)"],"pubmed_abstract":["Evidence for transcatheter aortic valve implantation (TAVI) is scarce among patients with non-calcific aortic stenosis, and it is not known whether aortic valve calcification is associated with new cerebral ischemic lesions (CILs) that are detected by diffusion-weighted magnetic resonance imaging. So, our study enrolled 328 patients who underwent transfemoral TAVI using a self-expanding valve between December 2016 and June 2021 from the TORCH registry (NCT02803294). A total of 34 patients were finally confirmed as non-calcific AS and the remaining 294 patients were included in the calcific AS group. Incidence of new CILs (70.6% vs. 85.7%, <i>p</i> = 0.022), number of lesions (2.0 vs. 3.0, <i>p</i> = 0.010), and lesions volume (105.0 mm<sup>3</sup> vs. 200.0 mm<sup>3</sup>, <i>p</i> = 0.047) was significantly lower in the non-calcific AS group. However, the maximum and average lesion volumes were comparable between two groups. Non-calcific AS was associated with lower risk for developing new CILs by univariate logistic regression analysis [Odds ratio (OR): 0.040, 95% confident interval (CI): 0.18-0.90, <i>p</i> = 0.026] and multivariate analysis (OR: 0.031, 95% CI: 0.13-0.76, <i>p</i> = 0.010). In summary, non-calcific AS patients had a lower risk of developing new cerebral ischemic infarction after TAVI compared to calcific AS patients. However, new ischemic lesions were still found in over 70% of patients."],"journal":["Journal of clinical medicine"],"pubmed_title":["Cerebral Ischemic Lesions after Transcatheter Aortic Valve Implantation in Patients with Non-Calcific Aortic Stenosis."],"pmcid":["PMC9655232"],"funding_grant_id":["81770252","JBZX-202001","81870292","2022C03063","81570233","2019YFA0110400","2018C03084","2021C03097"],"pubmed_authors":["Chen J","Guo Y","Liu Q","Zhu G","Wei Y","Wang J","Yidilisi A","Liu X","He Y","Fan J","Qi X","Zhou D","Zhu Q","Dai H"],"additional_accession":[]},"is_claimable":false,"name":"Cerebral Ischemic Lesions after Transcatheter Aortic Valve Implantation in Patients with Non-Calcific Aortic Stenosis.","description":"Evidence for transcatheter aortic valve implantation (TAVI) is scarce among patients with non-calcific aortic stenosis, and it is not known whether aortic valve calcification is associated with new cerebral ischemic lesions (CILs) that are detected by diffusion-weighted magnetic resonance imaging. So, our study enrolled 328 patients who underwent transfemoral TAVI using a self-expanding valve between December 2016 and June 2021 from the TORCH registry (NCT02803294). A total of 34 patients were finally confirmed as non-calcific AS and the remaining 294 patients were included in the calcific AS group. Incidence of new CILs (70.6% vs. 85.7%, <i>p</i> = 0.022), number of lesions (2.0 vs. 3.0, <i>p</i> = 0.010), and lesions volume (105.0 mm<sup>3</sup> vs. 200.0 mm<sup>3</sup>, <i>p</i> = 0.047) was significantly lower in the non-calcific AS group. However, the maximum and average lesion volumes were comparable between two groups. Non-calcific AS was associated with lower risk for developing new CILs by univariate logistic regression analysis [Odds ratio (OR): 0.040, 95% confident interval (CI): 0.18-0.90, <i>p</i> = 0.026] and multivariate analysis (OR: 0.031, 95% CI: 0.13-0.76, <i>p</i> = 0.010). In summary, non-calcific AS patients had a lower risk of developing new cerebral ischemic infarction after TAVI compared to calcific AS patients. However, new ischemic lesions were still found in over 70% of patients.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-25T23:27:04.965Z","creation":"2025-04-06T09:21:16.19Z"},"accession":"S-EPMC9655232","cross_references":{"pubmed":["36362730"],"doi":["10.3390/jcm11216502"]}}